Skip to main content


Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis

Fig. 5

Iguratimod regulates ASC differentiation in naive RA patients. Six naive and active RA patients received iguratimod monotherapy (50 mg/day) for 12 weeks. a FCM plots from one representative patient were shown for the changes of peripheral ASC frequencies along the time by the Boolean gating of ASCs and B cells in Flowjo. bf ASC frequencies (b), ASC numbers (c), B cell numbers (d), and disease activities calculated by DSR28-ESR and DSR28-CRP (e and f) were shown before and after treatment (n = 6). g The correlation between ASC frequencies and DSR28-CRP was shown. h EGR1, BLIMP1, XBP1, and PAX5 mRNAs were detected from PBMC by qRT-PCR (n = 6). One representative experiment out of 3 was shown. Data were analyzed with Spearman’s correlation (g) or with RM one-way ANOVA with Bonferroni correction for multiple comparisons (bf, h). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page